RCM
CELU icon

Radcliffe Capital Management’s Celularity CELU Stock Holding History

Radcliffe Capital Management’s Portfolio CELU Stock Details CELU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-8,729
Closed -$889K – 900
2021
Q2 		$889K Hold
8,729
– – 0.03% 761
2021
Q1 		$880K Sell
8,729
-5,000
-36% -$512K 0.04% 596
2020
Q4 		$1.51M Sell
13,729
-261
-2% -$27.7K 0.09% 248
2020
Q3 		$1.47M Sell
13,990
-4,110
-23% -$426K 0.13% 136
2020
Q2 		$1.85M Buy
18,100
+5,000
+38% +$496K 0.25% 69
2020
Q1 		$1.28M Buy
+13,100
New +$1.3M 0.24% 73

Other funds holding CELU

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $727M AUM 41.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Radcliffe Capital Management's CELU Position: Q3 2021 in Review

Radcliffe Capital Management sold out of Celularity (CELU) in Q3 2021, closing a stake of 8,729 shares — an estimated $889K sold.

Radcliffe Capital Management first reported a position in CELU in Q1 2020 and held it in 6 quarters. The position peaked at $1.85M in Q2 2020. 21 funds tracked by Wall St. Rank hold CELU as of Q3 2021.

  • Radcliffe Capital Management reported no remaining Celularity position as of Q3 2021 after selling out during the quarter.
  • Radcliffe Capital Management sold 8,729 Celularity shares in Q3 2021, an estimated $889K.
  • Radcliffe Capital Management first reported a position in Celularity in Q1 2020 and held it in 6 quarters.
  • Radcliffe Capital Management's Celularity position peaked at $1.85M in Q2 2020.
  • 21 funds tracked by Wall St. Rank held Celularity as of Q3 2021.

Based on Radcliffe Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.